Skip to main content
Top
Published in: Diabetologia 7/2004

01-07-2004 | Research Letter

Neonatal oral administration of DiaPep277, combined with hydrolysed casein diet, protects against Type 1 diabetes in BB-DP rats. An experimental study

Authors: S. Brugman, F. A. Klatter, J. Visser, N. A. Bos, D. Elias, J. Rozing

Published in: Diabetologia | Issue 7/2004

Login to get access

Abstract

Aims/hypothesis

Environmental factors such as diet and bacterial antigens play an important role in the onset of Type 1 diabetes. Different self-antigens are suggested to play a role in the development of diabetes. Antibodies against the 60-kDa heat shock protein 60, which have a high homology to bacterial heat shock protein 65, have been found in the circulation at the onset of diabetes in humans and in pre-diabetic NOD-mice. One of the immunodominant epitopes in autoimmune diabetes is p277, a specific peptide of human heat shock protein 60 corresponding to positions 437–460. In this study we investigated whether neonatal oral administration of DiaPep277 (a synthetic peptide analogue of p277) affected the development of diabetes in the BioBreeding-Diabetes Prone (BB-DP) rat, and whether this could potentiate the effect of a protective hydrolysed casein-diet.

Methods

BB-DP rats were orally inoculated once per day with placebo or DiaPep277 at days 4, 5, 6 and 7 of life. At the age of 21 days rats were weaned on to a conventional, cereal-based diet or on to the hydrolysed casein-diet.

Results

The development of diabetes in animals receiving DiaPep277 in combination with the hydrolysed casein-diet was delayed by 17 days, and a relative reduction of the incidence by 64% was seen. Non-diabetic animals did not show any sign of insulitis.

Conclusions/interpretation

Short-term neonatal feeding with p277 in early life, combined with diet adaptation, appears to provide a procedure to significantly reduce the development of Type 1 diabetes in later life.
Literature
1.
go back to reference Cohen IR (2002) Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia 45:1468–1474CrossRefPubMed Cohen IR (2002) Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia 45:1468–1474CrossRefPubMed
2.
go back to reference Yoon JW, Jun HS (2001) Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann NY Acad Sci 928:200–211CrossRefPubMed Yoon JW, Jun HS (2001) Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann NY Acad Sci 928:200–211CrossRefPubMed
3.
go back to reference Petersen JS, Karlsen AE, Markholst H, Worsaae A, Dyrberg T, Michelsen B (1994) Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 44:1478–1484CrossRef Petersen JS, Karlsen AE, Markholst H, Worsaae A, Dyrberg T, Michelsen B (1994) Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 44:1478–1484CrossRef
4.
go back to reference Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL (2001) Oral administration of insulin in neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 16:21–28CrossRefPubMed Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL (2001) Oral administration of insulin in neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 16:21–28CrossRefPubMed
5.
go back to reference Elias D, Meilin A, Ablamunits V et al. (1997) Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and down-regulates autoimmunity to various beta-cell antigens. Diabetes 46:758–764CrossRefPubMed Elias D, Meilin A, Ablamunits V et al. (1997) Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and down-regulates autoimmunity to various beta-cell antigens. Diabetes 46:758–764CrossRefPubMed
6.
go back to reference Visser J, Brugman S, Klatter F et al. (2003) Short-term dietary adjustment with a hydrolysed casein-based diet postpones diabetes development in the diabetes prone BB rat. Metabolism 52:333–337CrossRefPubMed Visser J, Brugman S, Klatter F et al. (2003) Short-term dietary adjustment with a hydrolysed casein-based diet postpones diabetes development in the diabetes prone BB rat. Metabolism 52:333–337CrossRefPubMed
7.
go back to reference Scott FW, Cloutier HE, Kleemann R et al. (1997) Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats. Diabetes 46:589–598CrossRefPubMed Scott FW, Cloutier HE, Kleemann R et al. (1997) Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats. Diabetes 46:589–598CrossRefPubMed
8.
go back to reference Mordes JP, Bortell R, Groen H, Guberski DL, Rossini AA, Greiner D (2001) Autoimmune diabetes mellitus in the BB rat. In: Sima AAF, Shafrir E (eds) Animal models for autoimmune diseases. Harwood, Amsterdam, pp 1–41 Mordes JP, Bortell R, Groen H, Guberski DL, Rossini AA, Greiner D (2001) Autoimmune diabetes mellitus in the BB rat. In: Sima AAF, Shafrir E (eds) Animal models for autoimmune diseases. Harwood, Amsterdam, pp 1–41
Metadata
Title
Neonatal oral administration of DiaPep277, combined with hydrolysed casein diet, protects against Type 1 diabetes in BB-DP rats. An experimental study
Authors
S. Brugman
F. A. Klatter
J. Visser
N. A. Bos
D. Elias
J. Rozing
Publication date
01-07-2004
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1452-1

Other articles of this Issue 7/2004

Diabetologia 7/2004 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.